- Details
- Matthew Milowsky joins Sam Chang in a discussion on the patient-reported outcomes from Cohort K of the EV-103 Phase 1b/2 study which analyzed the impact of enfortumab vedotin (EV) alone or combined with pembrolizumab on patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin. The objective was to describe the impact on the patients' quality of life (QoL)...
|
- Details
- Michiel Van der Heijden joins Alicia Morgans to discuss the NABUCCO trial, which investigated preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer. The study enrolled patients with Stage 3 disease, including both cisplatin-ineligible and cisplatin-refusing patients, with about 40% being node-positive. In cohort 1, high pathological complete response rates were observ...
|
- Details
- Matt Galsky joins Sam Chang in a conversation about the long-term results of CheckMate 274, a randomized phase III study that enrolled patients with muscle-invasive urothelial cancer at high risk for recurrence after radical surgery. Patients were randomized to receive adjuvant nivolumab or placebo, with adjuvant nivolumab given for up to a year. The study's co-primary endpoints were disease-free...
|
- Details
- Srikala Sridhar joins Sam Chang in discussing long-term follow-up from the JAVELIN Bladder 100 trial of avelumab first-line maintenance for advanced urothelial carcinoma. The JAVELIN-100 study was conducted on patients with metastatic urothelial carcinoma who had received frontline platinum-based chemotherapy and achieved a disease response. These patients were then randomized to receive either av...
|
- Details
- Sam Chang is joined in conversation by Gopa Iyer, discussing an article in European Urology that examines the predictive nature of FGFR3 wild-type versus mutant-type and its impact on patient response to perioperative chemotherapy in urothelial carcinoma. The study sought to evaluate the association between FGFR3 alterations and response to platinum-based chemotherapy, both in the perioperative as...
|
- Details
- Alicia Morgans is joined by Andrea Necchi in a conversation on the CheckMate 274 trial, the use of biomarkers in the adjuvant setting, and how they can be used to understand the effect of nivolumab. Necchi and colleagues performed an exploratory analysis to assess the association between disease-free survival (DFS) and biomarkers (continuous scale) and estimate treatment-effect hazard ratios for b...
|
- Details
- Andrea Necchi joins Alicia Morgans in a conversation about the FIDES-02 Study. This Phase 1b/2 study evaluated the efficacy and safety of derazantinib, a multi-TKI oral inhibitor that targets FGF receptor genomic alteration 1, 2, 3, and 4 genomic alterations, in patients with metastatic urothelial carcinoma. The focus is metastatic local advanced or metastatic patients with urothelial carcinoma of...
|
- Details
- Michiel Van der Heijden discusses two abstracts on the use of immunotherapy in bladder cancer during his discussion with Alicia Morgans. The first abstract looked at the use of pembrolizumab in patients with non-muscle invasive bladder cancer, specifically those with high-grade TA or T1 disease that is refractory to BCG treatment. The study showed a 43% recurrence-free survival rate at one year, m...
|
- Details
- Petros Grivas joins Alicia Morgans in a discussion on updated results of the phase II TROPHY-U-01 data from cohort 3, looking at the combination of pembrolizumab, anti-PD-1, plus sacituzumab govitecan, an antibody-drug conjugate against Trop-2 evaluated in 41 patients who had early progression resistance to platinum-based chemotherapy as a second-line therapy. Biographies: Petros Grivas, MD, Ph.D....
|
- Details
- Andrea Apolo, head of the bladder cancer section of the genitourinary malignancy branch within the NCI, joins Sam Chang to discuss first-line therapies for patients with advanced and metastatic urothelial carcinoma. Dr. Apolo explains that several clinical trials have been developed to improve outcomes in patients in the first-line setting by combining chemotherapy with checkpoint inhibitors. One...
|
